

Supplementary materials for

Population-scale patient safety data reveal inequalities in adverse events before and during COVID-19 pandemic

Xiang Zhang¹, Marissa Sumathipala¹, and Marinka Zitnik^{1,2,3,‡}

¹Department of Biomedical Informatics, Harvard University, Boston, MA 02115, USA

²Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

³Harvard Data Science Initiative, Cambridge, MA 02138, USA

‡Corresponding author. Email: marinka@hms.harvard.edu

This PDF file includes:

Supplementary Figures 1 to 9

Supplementary Tables 1 to 9

Contents

List of Figures

S1	Number of identified adverse events across demographic groups.	S3
S2	Distribution of <u>enriched</u> adverse events by organ type and demographic group.	S4
S3	Distribution of <u>purified</u> adverse events by organ type and demographic group.	S5
S4	Gender gap in <u>all patients</u> normalized by population size.	S6
S5	Gender gap in <u>adults</u> normalized by population size.	S7
S6	Gender gap in <u>elderly</u> normalized by population size.	S8
S7	Comparison of <u>proportion of male patients in enriched adverse events before and during the pandemic</u>	S9
S8	Comparison of reporter distribution in purified adverse events before and during the pandemic (continued in Figure S9).	S10
S9	Comparison of reporter distribution of purified adverse events before and during the pandemic (continued).	S11

List of Tables

S1	Summary of adverse events identified by our approach in <u>all patients</u>	S12
S2	Summary of adverse events identified by our approach in <u>male patients</u>	S14
S3	Summary of adverse events identified by our approach in <u>female patients</u>	S15
S4	Summary of adverse events identified by our approach in <u>young patients</u>	S17
S5	Summary of adverse events identified by our approach in <u>adult patients</u>	S17
S6	Summary of adverse events identified by our approach in <u>elderly patients</u>	S19
S7	Associations between adverse events and the pandemic.	S20
S8	Associations between adverse events and drugs.	S23
S9	Associations between drug-adverse event pairs and the pandemic.	S26

1 Supplementary Figures




Figure S1: Number of identified adverse events across demographic groups. Enriched adverse events refer to the drug side effects that are reported more often during the pandemic compared to before the pandemic, while purified ones are less reported. Although the total amount of reports submitted in the pandemic period (March 11 – September 30, 2020) has dropped to 211,152 in contrast to 220,920 before the pandemic (March 11 – September 30, 2019), we find that the enriched adverse drug reactions are more than, if not equal to, the purified ones. In terms of all patients, the number of enriched adverse events is 5.4 times more than the purified adverse events. This disparity is consistently observed across demographic groups including men (5.33 \times), women (6.33 \times), adults (17.5 \times), and elderly (18 \times). We find female patients suffer from more enriched adverse events than male patients; adults undergo more than young and aged individuals. Adjusted by the size of populations (per million patients), we find 48.5 adverse events with higher reporting frequency in response to the pandemic in women, whereas only 33.0 in men; there are only 27.8 enriched adverse drug reactions in young people, which is smaller than its counterparts in grow-ups (68.8) and older patients (58.9).

Distribution of enriched adverse events by organ type and demographic group




Figure S2: Distribution of enriched adverse events by organ type and demographic groups. The colors represent organ types (based on system organ class in MedDRA hierarchy; Methods) and the legend is the same as in Figure 2a. We find the enriched adverse events distribute unequally across organ systems. For example, psychology-related side effects are commonly found in male patients but not in female patients. Our model also detects the different distribution between the overall population and diverse patient cohorts. There are nine adverse events related to the nervous system regarding all patients, however, only one in adults and two in the elderly.

Distribution of purified adverse events by organ type and demographic group




Figure S3: Distribution of purified adverse events by organ type and demographic groups. The legend is the same as in Figure 2a where color represents organ systems according to the system organ class (SOC) in MedDRA ontology. This figure presents the adverse events, identified by our framework, which is triggered less frequently during the pandemic, only consider the reports submitted by healthcare professionals (Methods). For example, we find 4 out of 10 purified adverse events in all patients are related to renal disorders, one possible reason is that the diagnosis of renal adverse events highly depends on professional medical facilities which are insufficient during the pandemic. To further take into account the cases reported by nonprofessionals, we investigate the distribution of reporters' qualification of each purified adverse events (Figure S8; Figure S9).




Figure S4: Gender gap in all patients normalized by population size. We provide the incidence proportion (*i.e.*, the number of reports regarding a specific adverse event in 1,000 patients) of the enriched adverse events. This figure corresponds to Figure 2c (in the main text) whose y-axis shows the absolute number of reports. We find that gender disparity is increased in most adverse events (62.3%) during the pandemic compared to before the pandemic.




Figure S5: Gender gap in adults normalized by population size. Corresponding to Figure 3c that shows the absolute number of reports, the y-axis in this figure presents the relative number of reports adjusted by the number of adult patients (before and during the pandemic, respectively). For better comparison with the counterparts in all patients, we provide all adverse events as shown in the Figure S4. The adverse events with zero reports per thousand adults are not significantly associated with the pandemic in adults (although significant in the overall population), or are only observed in unknown sex. Among 24 drug reactions with gender disparities, we find that 17 experience a larger gender gap during the pandemic.




Figure S6: Gender gap in elderly normalized by population size. This figure corresponds to Figure 3d with different y-axis (the y-axis in this figure presents the relative number of reports adjusted by the number of elderly patients (before and during the pandemic, respectively)). For better comparison with the counterparts in all patients, we provide all adverse events as shown in Figure S4. The adverse events with zero reports per thousand patients are not significantly associated with the pandemic in elderly (although significant in terms of all patients), or are only observed in unknown sex. We find most (78.6%) of pre-exist gender gaps are increased during the pandemic. For example, before the pandemic, there are 11.33 reports involving confusional state in each thousand female patients, which is 2.47 more than its counterpart in male patients (8.86); the gender difference grows to 5.08 during the pandemic (17.58 in men; 12.5 in women).




Figure S7: Comparison of proportion of male patients in enriched adverse events before and during the pandemic.

We present the percentage of men (omit unknown sex) in adverse event reports, corresponding to Figure 2b which shows the proportion of female patients. The annotation shows the increased magnitude during the pandemic (March 11 – September 30, 2020) compared to before the pandemic (March 11 – September 30, 2019). We find the proportion of male patients are increased in 13 out of 53 enriched adverse events during pandemic period. For example, among the reports contains hypogammaglobulinaemia as drug side effect, there are only 29.5% occurred in men before the pandemic but jumped to 58.9% after pandemic onset, claiming an increased margin of 29.4%.




Figure S8: Comparison of reporter distribution in purified adverse events before and during the pandemic (continued in Figure S9). The adverse event reports in FAERS are submitted by five categories of reporters: physician, pharmacist, other professionals (such as nurses), lawyer, and customer. Based on the reports submitted by healthcare professionals (the first three qualifications), our approach identifies 10 purified adverse events in all populations. Here, we provide fine-grained reporter distribution by extending to nonprofessional reporters (the last two qualifications). The y-axis shows the number of reports per 1,000 patients and the annotations in brackets present the absolute number of reports.




Figure S9: Comparison of reporter distribution of purified adverse events before and during the pandemic (continued). Although the incidence proportion are decreased in reports submitted by professionals, we find five adverse events (infective pulmonary exacerbation of cystic fibrosis, chronic kidney disease, osteonecrosis of jaw, renal injury, and nausea) have more self-reported cases (submitted by customer themselves) during the pandemic in contrast to before pandemic. In particular, reports of kidney injury have dropped dramatically among professionals, but have risen sharply among non-professionals, which indicates that patients suffer from kidney injury do not have sufficient professional medical resources during the pandemic.

2 Supplementary Tables

Table S1: Summary of adverse events identified by our approach in all patients. Shown are 64 adverse events (54 enriched and 10 purified) are identified in the overall population by the proposed framework (Figure 1.a). This table shows the name of adverse events and their corresponding identifier in MedDRA ontology (<https://www.meddra.org/how-to-use/basics/hierarchy>). The reporting odds ratio β represents the association between adverse event and the pandemic (Fisher's exact test; p-value is adjusted by Bonferroni correction; Methods). The numbers in square brackets show the range of lower to upper 95% confidence interval. Higher β and smaller p-value indicate the adverse event has stronger association with the pandemic. The defined PAEAI presents the extent (higher PAEAI suggests larger deviation) that adverse event deviates from its historical trend (Methods). All identified adverse events have positive PAEAI which indicates the reporting pattern during the pandemic doesn't follow its trajectory. The adverse events are sorted in descending order of PAEAI. The 'E' and 'P' in the 'E\P' column denotes this adverse event is enriched or purified, respectively. PEx: pulmonary exacerbations.

Adverse event	MedDRA ID	β (95% CI)	p-value	PAEAI (\downarrow)	E\P
Delusion	10012239	2.53 [2.08,3.07]	$< 1.6 \times 10^{-18}$	1.95	E
Hypothermia	10021113	2.44 [1.79,3.33]	$< 4.0 \times 10^{-5}$	1.67	E
Internal haemorrhage	10075192	2.47 [1.92,3.18]	$< 2.0 \times 10^{-9}$	1.64	E
Respiratory failure	10038695	1.36 [1.24,1.49]	$< 1.0 \times 10^{-7}$	1.58	E
Hypogammaglobulinaemia	10020983	7.68 [5.14,11.48]	$< 4.0 \times 10^{-31}$	1.54	E
Bradycardia	10006093	1.38 [1.22,1.56]	$< 1.8 \times 10^{-3}$	1.42	E
Shock haemorrhagic	10049771	2.50 [1.76,3.55]	$< 1.0 \times 10^{-3}$	1.40	E
Neutrophilia	10029379	2.54 [2.02,3.20]	$< 7.6 \times 10^{-13}$	1.32	E
Neuroleptic malignant syndrome	10029282	2.52 [1.77,3.58]	$< 7.3 \times 10^{-4}$	1.30	E
Infective PEx of cystic fibrosis	10070608	0.52 [0.46,0.59]	$< 2.6 \times 10^{-19}$	1.28	P
Influenza like illness	10022004	0.77 [0.70,0.86]	$< 1.4 \times 10^{-2}$	1.26	P
Granulocytopenia	10018687	0.19 [0.13,0.29]	$< 2.4 \times 10^{-16}$	1.25	P
Haemorrhagic stroke	10019016	2.44 [1.80,3.29]	$< 1.4 \times 10^{-5}$	1.24	E
Dementia	10012267	1.68 [1.41,2.00]	$< 3.5 \times 10^{-5}$	1.24	E
Melanocytic naevus	10027145	2.78 [2.04,3.79]	$< 8.7 \times 10^{-8}$	1.23	E
Dystonia	10013983	2.51 [1.88,3.34]	$< 7.0 \times 10^{-7}$	1.23	E
Dizziness postural	10013578	2.05 [1.61,2.62]	$< 3.6 \times 10^{-5}$	1.22	E
Premature delivery	10036595	1.82 [1.49,2.21]	$< 2.1 \times 10^{-5}$	1.20	E
Hallucination	10019063	2.42 [2.21,2.65]	$< 5.7 \times 10^{-88}$	1.18	E
Hypoxia	10021143	1.48 [1.33,1.64]	$< 8.0 \times 10^{-9}$	1.13	E
Chronic kidney disease	10064848	0.31 [0.29,0.34]	$< 2.4 \times 10^{-165}$	1.12	P
Pain in jaw	10033433	1.74 [1.57,1.93]	$< 4.9 \times 10^{-22}$	1.10	E
Vitreous floaters	10047654	3.85 [2.91,5.10]	$< 3.1 \times 10^{-21}$	1.09	E
Pulmonary hypertension	10037400	1.51 [1.32,1.72]	$< 5.5 \times 10^{-6}$	1.06	E
Cardiac disorder	10061024	1.31 [1.18,1.45]	$< 2.5 \times 10^{-3}$	1.06	E
Hypotension	10021097	1.18 [1.11,1.25]	$< 1.3 \times 10^{-4}$	1.05	E

Urinary tract infection	10046571	1.37 [1.29,1.46]	$< 2.3 \times 10^{-19}$	1.04	E
Pain in extremity	10033425	1.21 [1.15,1.28]	$< 1.4 \times 10^{-8}$	1.04	E
Renal injury	10061481	0.24 [0.20,0.29]	$< 6.8 \times 10^{-57}$	1.03	P
Neuropathy peripheral	10029331	1.92 [1.78,2.08]	$< 7.1 \times 10^{-60}$	1.02	E
Cardiac arrest	10007515	1.93 [1.76,2.11]	$< 1.2 \times 10^{-43}$	1.00	E
Bladder cancer	10005003	2.59 [1.96,3.43]	$< 2.2 \times 10^{-8}$	0.95	E
Pyrexia	10037660	1.20 [1.14,1.26]	$< 3.5 \times 10^{-8}$	0.93	E
Tubulointerstitial nephritis	10048302	0.61 [0.51,0.74]	$< 5.0 \times 10^{-3}$	0.92	P
Fluid overload	10016803	1.38 [1.21,1.58]	$< 2.3 \times 10^{-2}$	0.91	E
Hypertension	10020772	1.26 [1.18,1.36]	$< 1.8 \times 10^{-6}$	0.88	E
Gait disturbance	10017577	1.37 [1.27,1.47]	$< 4.5 \times 10^{-14}$	0.85	E
Respiratory arrest	10038669	6.85 [5.46,8.60]	$< 1.1 \times 10^{-87}$	0.83	E
Chest pain	10008479	1.18 [1.10,1.26]	$< 2.8 \times 10^{-2}$	0.74	E
Visual acuity reduced	10047531	2.76 [2.05,3.71]	$< 1.8 \times 10^{-8}$	0.71	E
Pneumonia	10035664	1.14 [1.09,1.19]	$< 2.2 \times 10^{-4}$	0.71	E
Hypoacusis	10048865	1.82 [1.60,2.08]	$< 7.8 \times 10^{-16}$	0.69	E
End stage renal disease	10077512	0.38 [0.33,0.44]	$< 1.6 \times 10^{-33}$	0.67	P
Psoriatic arthropathy	10037162	1.43 [1.28,1.59]	$< 3.1 \times 10^{-6}$	0.64	E
Cognitive disorder	10057668	1.46 [1.26,1.70]	$< 3.7 \times 10^{-3}$	0.62	E
Rectal haemorrhage	10038063	1.55 [1.33,1.81]	$< 1.8 \times 10^{-4}$	0.59	E
Memory impairment	10027175	1.35 [1.25,1.46]	$< 2.5 \times 10^{-10}$	0.59	E
Neurotoxicity	10029350	1.45 [1.25,1.69]	$< 1.1 \times 10^{-2}$	0.58	E
Chest discomfort	10008469	1.27 [1.16,1.40]	$< 2.4 \times 10^{-3}$	0.53	E
Insomnia	10022437	1.19 [1.12,1.26]	$< 2.1 \times 10^{-4}$	0.52	E
Cough	10011224	1.23 [1.17,1.30]	$< 7.3 \times 10^{-10}$	0.48	E
Confusional state	10010305	1.40 [1.30,1.51]	$< 6.4 \times 10^{-15}$	0.46	E
Nausea	10028813	0.93 [0.90,0.96]	$< 1.7 \times 10^{-2}$	0.41	P
Gastrointestinal haemorrhage	10017955	1.68 [1.54,1.82]	$< 2.2 \times 10^{-31}$	0.41	E
Arthralgia	10003239	1.20 [1.15,1.26]	$< 1.7 \times 10^{-10}$	0.39	E
Osteonecrosis of jaw	10064658	0.57 [0.45,0.72]	$< 1.3 \times 10^{-2}$	0.33	P
Neoplasm progression	10061309	1.61 [1.43,1.82]	$< 1.6 \times 10^{-11}$	0.27	E
Anxiety	10002855	1.25 [1.17,1.33]	$< 9.0 \times 10^{-8}$	0.18	E
Dyspnoea	10013968	1.19 [1.15,1.24]	$< 3.1 \times 10^{-16}$	0.15	E
Agranulocytosis	10001507	0.38 [0.27,0.52]	$< 4.3 \times 10^{-6}$	0.15	P
Oedema peripheral	10030124	1.50 [1.37,1.64]	$< 3.0 \times 10^{-15}$	0.15	E
Fluid retention	10016807	1.44 [1.32,1.58]	$< 8.1 \times 10^{-12}$	0.13	E
Tremor	10044565	1.20 [1.11,1.29]	$< 3.8 \times 10^{-2}$	0.06	E
Haematuria	10018867	1.43 [1.23,1.66]	$< 3.9 \times 10^{-2}$	0.02	E

Table S2: Summary of adverse events identified by our approach in male patients. Shown are 19 adverse events including 16 enriched and 3 purified during the pandemic, which are identified in male subpopulation. The β represents the association between adverse event and the pandemic period (p-value is measured by Fisher's exact test, adjusted by Bonferroni correction). The adverse events are sorted in descending order of PAEAI. The 'E' and 'P' in the 'E/P' column denotes this adverse event is enriched or purified, respectively. More notations are the same as in SI Table S1. PEx: pulmonary exacerbations.

Adverse event	MedDRA ID	β (95% CI)	p-value	PAEAI (\downarrow)	E/P
Hypogammaglobulinaemia	10020983	22.32 [9.11,54.69]	$< 1.6 \times 10^{-23}$	1.91	E
Alcoholism	10001639	1.90 [1.45,2.49]	$< 1.7 \times 10^{-2}$	1.79	E
Delusion	10012239	2.96 [2.28,3.85]	$< 2.1 \times 10^{-14}$	1.59	E
Neutrophilia	10029379	4.20 [2.92,6.04]	$< 3.2 \times 10^{-14}$	1.48	E
Dementia	10012267	1.83 [1.41,2.38]	$< 2.8 \times 10^{-2}$	1.24	E
Hallucination	10019063	2.79 [2.46,3.18]	$< 4.9 \times 10^{-58}$	1.23	E
Infective PEx of cystic fibrosis	10070608	0.54 [0.44,0.67]	$< 3.9 \times 10^{-5}$	1.23	P
Cardiac arrest	10007515	1.89 [1.66,2.16]	$< 2.8 \times 10^{-18}$	1.12	E
Respiratory failure	10038695	1.40 [1.23,1.60]	$< 4.3 \times 10^{-3}$	0.96	E
Neuropathy peripheral	10029331	2.32 [2.05,2.63]	$< 1.0 \times 10^{-38}$	0.95	E
Internal haemorrhage	10075192	2.41 [1.70,3.42]	$< 2.4 \times 10^{-3}$	0.90	E
Respiratory arrest	10038669	8.19 [5.64,11.90]	$< 9.6 \times 10^{-41}$	0.80	E
Headache	10019211	0.83 [0.78,0.89]	$< 4.3 \times 10^{-4}$	0.76	P
Bradycardia	10006093	1.59 [1.32,1.93]	$< 1.0 \times 10^{-2}$	0.65	E
Rectal haemorrhage	10038063	1.86 [1.44,2.40]	$< 8.1 \times 10^{-3}$	0.61	E
Gastrointestinal haemorrhage	10017955	1.78 [1.58,2.02]	$< 3.8 \times 10^{-17}$	0.59	E
Confusional state	10010305	1.54 [1.38,1.73]	$< 4.0 \times 10^{-10}$	0.26	E
Gynaecomastia	10018800	0.55 [0.43,0.70]	$< 4.5 \times 10^{-3}$	0.21	P
Cytokine release syndrome	10052015	1.81 [1.45,2.24]	$< 3.7 \times 10^{-4}$	0.08	E

Table S3: Summary of adverse events identified by our approach in female patients. Shown are 44 adverse events including 38 enriched and 6 purified during the pandemic, identified in female subpopulation. The β represents the association between adverse event and the pandemic period (p-value is measured by Fisher’s exact test, adjusted by Bonferroni correction). The adverse events are sorted in descending order of PAEAI. The ‘E’ and ‘P’ in the ‘E\P’ column denotes this adverse event is enriched or purified, respectively. More notations are the same as in SI Table S1. PEx: pulmonary exacerbations, PPE: Palmar-plantar erythrodysesthesia syndrome.

Adverse event	MedDRA ID	β (95% CI)	p-value	PAEAI (\downarrow)	E/P
Premature delivery	10036595	1.84 [1.50,2.25]	$< 2.4 \times 10^{-5}$	2.53	E
Dizziness postural	10013578	2.46 [1.76,3.45]	$< 4.7 \times 10^{-4}$	1.44	E
Hypotension	10021097	1.26 [1.17,1.37]	$< 6.0 \times 10^{-5}$	1.37	E
Pulmonary hypertension	10037400	1.73 [1.47,2.04]	$< 1.7 \times 10^{-7}$	1.34	E
Hallucination	10019063	2.10 [1.83,2.41]	$< 1.6 \times 10^{-23}$	1.26	E
Neuropathy peripheral	10029331	1.84 [1.66,2.05]	$< 7.4 \times 10^{-27}$	1.23	E
Pain in extremity	10033425	1.21 [1.14,1.29]	$< 1.9 \times 10^{-5}$	1.21	E
Infective PEx of cystic fibrosis	10070608	0.50 [0.42,0.60]	$< 3.6 \times 10^{-11}$	1.21	P
Melanocytic naevus	10027145	3.08 [2.15,4.41]	$< 4.0 \times 10^{-7}$	1.20	E
Pain in jaw	10033433	1.77 [1.57,2.00]	$< 3.0 \times 10^{-17}$	1.10	E
Hypoxia	10021143	1.51 [1.31,1.75]	$< 2.3 \times 10^{-4}$	1.03	E
Urinary tract infection	10046571	1.38 [1.28,1.48]	$< 1.0 \times 10^{-13}$	0.98	E
Confusional state	10010305	1.28 [1.15,1.42]	$< 4.4 \times 10^{-2}$	0.94	E
Fluid overload	10016803	1.56 [1.32,1.86]	$< 2.2 \times 10^{-3}$	0.92	E
Cardiac arrest	10007515	2.04 [1.78,2.34]	$< 9.1 \times 10^{-23}$	0.88	E
Gait disturbance	10017577	1.34 [1.22,1.46]	$< 4.4 \times 10^{-6}$	0.84	E
Hypertension	10020772	1.33 [1.21,1.46]	$< 6.0 \times 10^{-5}$	0.83	E
Pneumonia	10035664	1.27 [1.20,1.35]	$< 8.1 \times 10^{-11}$	0.83	E
Insomnia	10022437	1.21 [1.11,1.31]	$< 3.6 \times 10^{-2}$	0.83	E
Pyrexia	10037660	1.31 [1.22,1.41]	$< 1.5 \times 10^{-9}$	0.81	E
Hypoacusis	10048865	1.96 [1.64,2.33]	$< 1.0 \times 10^{-10}$	0.77	E
Psoriatic arthropathy	10037162	1.51 [1.32,1.73]	$< 8.2 \times 10^{-6}$	0.75	E
Respiratory arrest	10038669	9.40 [6.60,13.40]	$< 7.1 \times 10^{-55}$	0.74	E
Influenza	10022000	1.33 [1.20,1.46]	$< 7.0 \times 10^{-5}$	0.70	E
Chest pain	10008479	1.27 [1.17,1.39]	$< 2.6 \times 10^{-4}$	0.68	E
Chest discomfort	10008469	1.44 [1.29,1.62]	$< 1.7 \times 10^{-6}$	0.68	E
Cough	10011224	1.33 [1.24,1.42]	$< 2.7 \times 10^{-12}$	0.66	E
Renal impairment	10062237	1.53 [1.27,1.84]	$< 4.1 \times 10^{-2}$	0.59	E
Gastrointestinal haemorrhage	10017955	2.03 [1.78,2.31]	$< 2.7 \times 10^{-23}$	0.57	E
Chronic kidney disease	10064848	0.41 [0.34,0.48]	$< 4.7 \times 10^{-25}$	0.55	P
PPE syndrome	10033553	0.53 [0.40,0.69]	$< 1.7 \times 10^{-2}$	0.47	P

Renal injury	10061481	0.33 [0.25,0.44]	$< 1.2 \times 10^{-11}$	0.43	P
Neoplasm progression	10061309	1.75 [1.52,2.01]	$< 8.9 \times 10^{-12}$	0.42	E
Palpitations	10033557	1.28 [1.15,1.41]	$< 3.0 \times 10^{-2}$	0.41	E
Anxiety	10002855	1.34 [1.24,1.45]	$< 2.3 \times 10^{-9}$	0.39	E
Back pain	10003988	1.21 [1.12,1.30]	$< 3.2 \times 10^{-3}$	0.39	E
Nausea	10028813	0.90 [0.87,0.93]	$< 1.0 \times 10^{-4}$	0.20	P
Dyspnoea	10013968	1.25 [1.19,1.31]	$< 3.9 \times 10^{-16}$	0.19	E
Fluid retention	10016807	1.55 [1.39,1.74]	$< 5.1 \times 10^{-11}$	0.17	E
Memory impairment	10027175	1.34 [1.21,1.47]	$< 3.1 \times 10^{-5}$	0.12	E
Flushing	10016825	1.28 [1.15,1.42]	$< 2.4 \times 10^{-2}$	0.10	E
Oedema peripheral	10030124	1.60 [1.42,1.79]	$< 1.1 \times 10^{-11}$	0.07	E
Arthralgia	10003239	1.17 [1.11,1.25]	$< 6.4 \times 10^{-4}$	0.02	E
Cardio-respiratory arrest	10007617	0.41 [0.33,0.52]	$< 3.7 \times 10^{-11}$	0.01	P

Table S4: Summary of adverse events identified by our approach in young patients. Our framework detects two adverse events (one enriched and one purified), which have significant different reporting pattern in the pandemic compared to before the pandemic, in young patients. The β represents the association between adverse event and the pandemic period (p-value is measured by Fisher’s exact test, adjusted by Bonferroni correction). The adverse events are sorted in descending order of PAEAI. The ‘E’ and ‘P’ in the ‘E\’P’ column denotes this adverse event is enriched or purified, respectively. More notations are the same as in SI Table S1. PEx: pulmonary exacerbations.

Adverse event	MedDRA ID	β (95% CI)	p-value	PAEAI (\downarrow)	E/P
Infective PEx of cystic fibrosis	10070608	0.48 [0.38,0.62]	$< 7.3 \times 10^{-6}$	1.33	P
Pyrexia	10037660	1.50 [1.26,1.78]	$< 1.1 \times 10^{-2}$	1.08	E

Table S5: Summary of adverse events identified by our approach in adult patients. Shown are 37 adverse events, including 35 enriched and 2 purified, identified in adults. The β represents the association between adverse event and the pandemic period (p-value is measured by Fisher’s exact test, adjusted by Bonferroni correction). The adverse events are sorted in descending order of PAEAI. The ‘E’ and ‘P’ in the ‘E\’P’ column denotes this adverse event is enriched or purified, respectively. More notations are the same as in SI Table S1. PEx: pulmonary exacerbations.

Adverse event	MedDRA ID	β (95% CI)	p-value	PAEAI (\downarrow)	E/P
Pain in jaw	10033433	1.93 [1.65,2.25]	$< 1.1 \times 10^{-13}$	1.61	E
Premature delivery	10036595	2.32 [1.86,2.90]	$< 1.7 \times 10^{-10}$	1.58	E
Pulmonary hypertension	10037400	2.14 [1.71,2.69]	$< 1.7 \times 10^{-7}$	1.48	E
Pulmonary arterial hypertension	10064911	1.82 [1.48,2.25]	$< 1.0 \times 10^{-4}$	1.43	E
Neutrophilia	10029379	4.96 [3.53,6.96]	$< 3.8 \times 10^{-22}$	1.34	E
Acute kidney injury	10069339	1.41 [1.28,1.55]	$< 1.5 \times 10^{-8}$	1.32	E
Melanocytic naevus	10027145	3.64 [2.52,5.26]	$< 8.5 \times 10^{-10}$	1.32	E
Respiratory failure	10038695	1.49 [1.29,1.72]	$< 3.0 \times 10^{-4}$	1.29	E
Pyrexia	10037660	1.29 [1.19,1.40]	$< 9.1 \times 10^{-6}$	1.22	E
Hypoxia	10021143	1.58 [1.33,1.87]	$< 1.0 \times 10^{-3}$	1.14	E
Pneumonia	10035664	1.22 [1.13,1.33]	$< 1.3 \times 10^{-2}$	1.12	E
Neuropathy peripheral	10029331	1.84 [1.58,2.15]	$< 3.9 \times 10^{-11}$	1.10	E
Haemorrhage	10055798	1.93 [1.61,2.32]	$< 5.0 \times 10^{-9}$	1.07	E
Cardiac arrest	10007515	2.71 [2.37,3.09]	$< 3.0 \times 10^{-50}$	1.01	E
Rectal haemorrhage	10038063	1.99 [1.50,2.64]	$< 9.7 \times 10^{-3}$	0.99	E
Hypotension	10021097	1.59 [1.44,1.75]	$< 1.6 \times 10^{-17}$	0.88	E
Bone marrow failure	10065553	0.41 [0.29,0.59]	$< 4.9 \times 10^{-3}$	0.87	P
Neutropenia	10029354	1.36 [1.21,1.53]	$< 1.4 \times 10^{-3}$	0.87	E
Pain in extremity	10033425	1.30 [1.19,1.41]	$< 6.8 \times 10^{-6}$	0.85	E
Respiratory arrest	10038669	20.18 [13.26,30.72]	$< 1.2 \times 10^{-99}$	0.85	E
Tachycardia	10043071	1.46 [1.26,1.69]	$< 5.4 \times 10^{-3}$	0.84	E

Chest pain	10008479	1.32 [1.20,1.47]	$< 5.3 \times 10^{-4}$	0.78	E
Gastrointestinal haemorrhage	10017955	2.82 [2.35,3.38]	$< 3.0 \times 10^{-28}$	0.77	E
Psoriatic arthropathy	10037162	1.74 [1.48,2.04]	$< 6.8 \times 10^{-8}$	0.73	E
Fluid overload	10016803	1.67 [1.37,2.03]	$< 1.7 \times 10^{-3}$	0.73	E
Arthralgia	10003239	1.23 [1.14,1.33]	$< 5.5 \times 10^{-4}$	0.72	E
Palpitations	10033557	1.43 [1.25,1.63]	$< 1.1 \times 10^{-3}$	0.65	E
Cough	10011224	1.53 [1.39,1.67]	$< 5.7 \times 10^{-16}$	0.63	E
Psoriasis	10037153	1.35 [1.23,1.48]	$< 3.5 \times 10^{-7}$	0.62	E
Cytokine release syndrome	10052015	1.84 [1.47,2.30]	$< 4.6 \times 10^{-4}$	0.62	E
Menorrhagia	10027313	1.81 [1.43,2.30]	$< 5.8 \times 10^{-3}$	0.61	E
Anxiety	10002855	1.36 [1.23,1.50]	$< 1.7 \times 10^{-5}$	0.56	E
Neoplasm progression	10061309	1.87 [1.54,2.28]	$< 1.4 \times 10^{-6}$	0.37	E
Dyspnoea	10013968	1.31 [1.23,1.39]	$< 3.3 \times 10^{-14}$	0.36	E
Chronic kidney disease	10064848	0.58 [0.47,0.72]	$< 2.6 \times 10^{-3}$	0.35	P
Oedema peripheral	10030124	1.57 [1.35,1.83]	$< 4.5 \times 10^{-5}$	0.30	E
Sinusitis	10040753	1.52 [1.34,1.72]	$< 2.9 \times 10^{-7}$	0.03	E

Table S6: Summary of adverse events identified by our approach in elderly patients. Shown are 19 adverse events (18 enriched and 1 purified), identified in aged individuals. The β represents the association between adverse event and the pandemic period (p-value is measured by Fisher’s exact test, adjusted by Bonferroni correction). The adverse events are sorted in descending order of PAEAI. The ‘E’ and ‘P’ in the ‘E\P’ column denotes this adverse event is enriched or purified, respectively. More notations are the same as in SI Table S1.

Adverse event	MedDRA ID	β (95% CI)	p-value	PAEAI (\downarrow)	E/P
Aggression	10001488	2.42 [1.70,3.45]	$< 2.1 \times 10^{-3}$	1.46	E
Vitreous floaters	10047654	8.11 [4.97,13.23]	$< 1.5 \times 10^{-22}$	1.40	E
Abnormal behaviour	10061422	2.85 [2.03,3.98]	$< 4.9 \times 10^{-7}$	1.16	E
Delusion	10012239	2.79 [2.09,3.72]	$< 9.3 \times 10^{-10}$	1.07	E
Haematuria	10018867	1.98 [1.55,2.54]	$< 1.5 \times 10^{-4}$	1.04	E
Hallucination	10019063	2.58 [2.24,2.97]	$< 1.1 \times 10^{-39}$	1.01	E
Cardiac arrest	10007515	1.59 [1.34,1.89]	$< 7.5 \times 10^{-4}$	0.99	E
Internal haemorrhage	10075192	2.92 [2.01,4.24]	$< 1.2 \times 10^{-5}$	0.97	E
Dementia	10012267	1.97 [1.51,2.58]	$< 2.4 \times 10^{-3}$	0.94	E
General physical health deterioration	10049438	1.97 [1.50,2.59]	$< 4.8 \times 10^{-3}$	0.91	E
Rectal haemorrhage	10038063	1.88 [1.47,2.39]	$< 1.1 \times 10^{-3}$	0.90	E
Urinary tract infection	10046571	1.29 [1.16,1.43]	$< 1.7 \times 10^{-2}$	0.89	E
Neuropathy peripheral	10029331	1.58 [1.36,1.84]	$< 1.0 \times 10^{-5}$	0.83	E
Acute kidney injury	10069339	1.35 [1.21,1.50]	$< 1.4 \times 10^{-4}$	0.83	E
Gastrointestinal haemorrhage	10017955	2.00 [1.78,2.26]	$< 2.9 \times 10^{-28}$	0.75	E
Hypoacusis	10048865	2.18 [1.78,2.66]	$< 2.1 \times 10^{-11}$	0.73	E
Confusional state	10010305	1.51 [1.34,1.70]	$< 9.0 \times 10^{-8}$	0.73	E
Nausea	10028813	0.85 [0.80,0.91]	$< 2.4 \times 10^{-2}$	0.63	P
Neoplasm progression	10061309	1.92 [1.61,2.30]	$< 5.7 \times 10^{-10}$	0.47	E

Table S7: Associations between adverse events and the pandemic. The ‘Occur 2019’ and ‘Nonoccur 2019’ denote the number of submitted reports that contain and not contain the specific adverse event in 2019 (March 11 – September 30), respectively. Similarly, ‘Occur 2020’ and ‘Nonoccur 2020’ denote the statistics in the same period of 2020. On the basis of these numbers, we calculate the defined β following Eq. 2 (Methods), which measures the association between the adverse event and the pandemic. The p-value is measured by Fisher’s exact test followed by Bonferroni correction. In this table, we focus on the adverse events that involved in at least 100 reports either in 2019 or 2020, and present the top 100 adverse events with the lowest p-values. Then, the adverse events are sorted in descending order of β . Higher β and smaller p-value indicate the adverse event has stronger association with the pandemic. PEx: pulmonary exacerbation; IEC: Immune effector cell.

Adverse event	Occur 2019	Nonoccur 2019	Occur 2020	Nonoccur 2020	β (95% CI) (\downarrow)	p-value
Vitritis	8	220,912	105	211,047	13.74 [6.69,28.19]	$< 8.0 \times 10^{-20}$
Hypogammaglobulinaemia	27	220,893	198	210,954	7.68 [5.14,11.48]	$< 4.0 \times 10^{-31}$
Respiratory arrest	86	220,834	562	210,590	6.85 [5.46,8.60]	$< 1.1 \times 10^{-87}$
Vitreous floaters	62	220,858	228	210,924	3.85 [2.91,5.10]	$< 3.0 \times 10^{-21}$
Eye inflammation	49	220,871	160	210,992	3.42 [2.48,4.71]	$< 3.1 \times 10^{-12}$
Uveitis	53	220,867	161	210,991	3.18 [2.33,4.34]	$< 4.3 \times 10^{-11}$
Melanocytic naevus	55	220,865	146	211,006	2.78 [2.04,3.79]	$< 8.7 \times 10^{-8}$
Hypoalbuminaemia	40	220,880	106	211,046	2.77 [1.93,3.99]	$< 6.3 \times 10^{-5}$
Visual acuity reduced	60	220,860	158	210,994	2.76 [2.05,3.71]	$< 1.8 \times 10^{-8}$
Bladder cancer	69	220,851	171	210,981	2.59 [1.96,3.43]	$< 2.2 \times 10^{-8}$
Neutrophilia	103	220,817	250	210,902	2.54 [2.02,3.20]	$< 7.6 \times 10^{-13}$
Delusion	143	220,777	345	210,807	2.53 [2.08,3.07]	$< 1.6 \times 10^{-18}$
Neuroleptic malignant syndrome	44	220,876	106	211,046	2.52 [1.77,3.58]	$< 7.2 \times 10^{-4}$
Dystonia	66	220,854	158	210,994	2.51 [1.88,3.34]	$< 7.0 \times 10^{-7}$
Shock haemorrhagic	44	220,876	105	211,047	2.50 [1.76,3.55]	$< 1.0 \times 10^{-3}$
Internal haemorrhage	86	220,834	203	210,949	2.47 [1.92,3.18]	$< 2.0 \times 10^{-9}$
Haemorrhagic stroke	61	220,859	142	211,010	2.44 [1.80,3.29]	$< 1.4 \times 10^{-5}$
Hypothermia	57	220,863	133	211,019	2.44 [1.79,3.33]	$< 4.0 \times 10^{-5}$
Hallucination	699	220,221	1,610	209,542	2.42 [2.21,2.65]	$< 5.7 \times 10^{-88}$
Sensitivity to weather change	48	220,872	102	211,050	2.22 [1.58,3.13]	$< 2.5 \times 10^{-2}$
Dizziness postural	97	220,823	190	210,962	2.05 [1.61,2.62]	$< 3.6 \times 10^{-5}$
Tachypnoea	91	220,829	171	210,981	1.97 [1.53,2.54]	$< 1.1 \times 10^{-3}$
Eye pain	251	220,669	473	210,679	1.97 [1.69,2.30]	$< 5.6 \times 10^{-15}$
Lymphopenia	95	220,825	178	210,974	1.96 [1.53,2.52]	$< 7.6 \times 10^{-4}$
Cardiac arrest	725	220,195	1,331	209,821	1.93 [1.76,2.11]	$< 1.2 \times 10^{-43}$
Cytokine release syndrome	282	220,638	520	210,632	1.93 [1.67,2.23]	$< 9.7 \times 10^{-16}$
Neuropathy peripheral	994	219,926	1,817	209,335	1.92 [1.78,2.08]	$< 7.1 \times 10^{-60}$
Premature delivery	154	220,766	267	210,885	1.82 [1.49,2.21]	$< 2.1 \times 10^{-5}$
Hypoacusis	350	220,570	609	210,543	1.82 [1.60,2.08]	$< 7.8 \times 10^{-16}$
Pain in jaw	562	220,358	934	210,218	1.74 [1.57,1.93]	$< 4.8 \times 10^{-22}$
Dry eye	246	220,674	400	210,752	1.70 [1.45,2.00]	$< 2.8 \times 10^{-7}$
Encephalopathy	262	220,658	422	210,730	1.69 [1.45,1.97]	$< 1.6 \times 10^{-7}$
Lower limb fracture	132	220,788	212	210,940	1.68 [1.35,2.09]	$< 2.3 \times 10^{-2}$
Dementia	206	220,714	331	210,821	1.68 [1.41,2.00]	$< 3.5 \times 10^{-5}$

Gastrointestinal haemorrhage	914	220,006	1,462	209,690	1.68 [1.54,1.82]	$< 2.2 \times 10^{-31}$
Restless legs syndrome	159	220,761	251	210,901	1.65 [1.35,2.02]	$< 5.3 \times 10^{-3}$
Ageusia	211	220,709	329	210,823	1.63 [1.37,1.94]	$< 2.3 \times 10^{-4}$
Neoplasm progression	451	220,469	694	210,458	1.61 [1.43,1.82]	$< 1.6 \times 10^{-11}$
Alcoholism	177	220,743	267	210,885	1.58 [1.31,1.91]	$< 2.3 \times 10^{-2}$
Rectal haemorrhage	270	220,650	401	210,751	1.55 [1.33,1.81]	$< 1.8 \times 10^{-4}$
Pulmonary hypertension	384	220,536	553	210,599	1.51 [1.32,1.72]	$< 5.5 \times 10^{-6}$
Nasal congestion	570	220,350	823	210,329	1.51 [1.36,1.68]	$< 2.0 \times 10^{-10}$
Oedema peripheral	815	220,105	1,168	209,984	1.50 [1.37,1.64]	$< 3.0 \times 10^{-15}$
Hypoxia	574	220,346	809	210,343	1.48 [1.33,1.64]	$< 7.9 \times 10^{-9}$
Rheumatoid arthritis	526	220,394	736	210,416	1.47 [1.31,1.64]	$< 1.7 \times 10^{-7}$
Cognitive disorder	301	220,619	421	210,731	1.46 [1.26,1.70]	$< 3.7 \times 10^{-3}$
Neurotoxicity	293	220,627	406	210,746	1.45 [1.25,1.69]	$< 1.1 \times 10^{-2}$
Fluid retention	826	220,094	1,138	210,014	1.44 [1.32,1.58]	$< 8.0 \times 10^{-12}$
Haematuria	293	220,627	399	210,753	1.43 [1.23,1.66]	$< 3.9 \times 10^{-2}$
Psoriatic arthropathy	541	220,379	737	210,415	1.43 [1.28,1.59]	$< 3.1 \times 10^{-6}$
Neoplasm malignant	344	220,576	459	210,693	1.40 [1.21,1.61]	$< 2.5 \times 10^{-2}$
Confusional state	1,229	219,691	1,638	209,514	1.40 [1.30,1.51]	$< 6.3 \times 10^{-15}$
Sinusitis	1,048	219,872	1,388	209,764	1.39 [1.28,1.50]	$< 1.0 \times 10^{-11}$
Bradycardia	455	220,465	601	210,551	1.38 [1.22,1.56]	$< 1.7 \times 10^{-3}$
Fluid overload	376	220,544	496	210,656	1.38 [1.21,1.58]	$< 2.3 \times 10^{-2}$
Urinary tract infection	1,735	219,185	2,272	208,880	1.37 [1.29,1.46]	$< 2.3 \times 10^{-19}$
Gait disturbance	1,347	219,573	1,758	209,394	1.37 [1.27,1.47]	$< 4.5 \times 10^{-14}$
Respiratory failure	871	220,049	1,130	210,022	1.36 [1.24,1.49]	$< 1.0 \times 10^{-7}$
Memory impairment	1,152	219,768	1,482	209,670	1.35 [1.25,1.46]	$< 2.5 \times 10^{-10}$
Epistaxis	637	220,283	800	210,352	1.32 [1.18,1.46]	$< 2.4 \times 10^{-3}$
Cardiac disorder	668	220,252	834	210,318	1.31 [1.18,1.45]	$< 2.5 \times 10^{-3}$
Chest discomfort	826	220,094	1,005	210,147	1.27 [1.16,1.40]	$< 2.4 \times 10^{-3}$
Hypertension	1,358	219,562	1,638	209,514	1.26 [1.18,1.36]	$< 1.8 \times 10^{-6}$
Anxiety	1,777	219,143	2,113	209,039	1.25 [1.17,1.33]	$< 9.0 \times 10^{-8}$
Peripheral swelling	2,136	218,784	2,511	208,641	1.23 [1.16,1.31]	$< 1.5 \times 10^{-8}$
Palpitations	914	220,006	1,073	210,079	1.23 [1.13,1.34]	$< 4.8 \times 10^{-2}$
Cough	2,451	218,469	2,874	208,278	1.23 [1.17,1.30]	$< 7.3 \times 10^{-10}$
Pain in extremity	2,613	218,307	3,014	208,138	1.21 [1.15,1.28]	$< 1.4 \times 10^{-8}$
Arthralgia	3,266	217,654	3,744	207,408	1.20 [1.15,1.26]	$< 1.7 \times 10^{-10}$
Pyrexia	2,762	218,158	3,160	207,992	1.20 [1.14,1.26]	$< 3.5 \times 10^{-8}$
Tremor	1,260	219,660	1,439	209,713	1.20 [1.11,1.29]	$< 3.8 \times 10^{-2}$
Insomnia	1,971	218,949	2,238	208,914	1.19 [1.12,1.26]	$< 2.1 \times 10^{-4}$
Dyspnoea	5,414	215,506	6,130	205,022	1.19 [1.15,1.24]	$< 3.0 \times 10^{-16}$
Chest pain	1,595	219,325	1,790	209,362	1.18 [1.10,1.26]	$< 2.8 \times 10^{-2}$
Hypotension	2,286	218,634	2,570	208,582	1.18 [1.11,1.25]	$< 1.3 \times 10^{-4}$
Back pain	2,121	218,799	2,322	208,830	1.15 [1.08,1.22]	$< 5.5 \times 10^{-2}$
Pneumonia	3,708	217,212	4,021	207,131	1.14 [1.09,1.19]	$< 2.2 \times 10^{-4}$
Nausea	9,373	211,547	8,349	202,803	0.93 [0.90,0.96]	$< 1.7 \times 10^{-2}$
Influenza like illness	835	220,085	619	210,533	0.77 [0.70,0.86]	$< 1.4 \times 10^{-2}$
Musculoskeletal pain	562	220,358	400	210,752	0.74 [0.65,0.85]	$< 5.9 \times 10^{-2}$

Anaphylactic reaction	653	220,267	459	210,693	0.73 [0.65,0.83]	$< 3.6 \times 10^{-3}$
Tubulointerstitial nephritis	278	220,642	163	210,989	0.61 [0.51,0.74]	$< 5.0 \times 10^{-3}$
Haemorrhoids	249	220,671	141	211,011	0.59 [0.48,0.73]	$< 4.6 \times 10^{-3}$
Osteonecrosis of jaw	198	220,722	107	211,045	0.57 [0.45,0.72]	$< 1.3 \times 10^{-2}$
Photosensitivity reaction	217	220,703	114	211,038	0.55 [0.44,0.69]	$< 1.4 \times 10^{-3}$
Dermatitis allergic	142	220,778	71	211,081	0.52 [0.39,0.70]	$< 5.2 \times 10^{-2}$
Infective PEx of cystic fibrosis	661	220,259	329	210,823	0.52 [0.46,0.59]	$< 2.5 \times 10^{-19}$
Diverticulum	120	220,800	55	211,097	0.48 [0.35,0.66]	$< 3.2 \times 10^{-2}$
Hiatus hernia	185	220,735	83	211,069	0.47 [0.36,0.61]	$< 3.1 \times 10^{-5}$
Cardio-respiratory arrest	473	220,447	212	210,940	0.47 [0.40,0.55]	$< 1.9 \times 10^{-17}$
Bone marrow failure	243	220,677	100	211,052	0.43 [0.34,0.54]	$< 1.4 \times 10^{-9}$
End stage renal disease	585	220,335	213	210,939	0.38 [0.33,0.44]	$< 1.6 \times 10^{-33}$
Agranulocytosis	141	220,779	51	211,101	0.38 [0.27,0.52]	$< 4.2 \times 10^{-6}$
Chronic kidney disease	2,113	218,807	640	210,512	0.31 [0.29,0.34]	$< 2.3 \times 10^{-165}$
Large intestine polyp	135	220,785	38	211,114	0.29 [0.21,0.42]	$< 4.0 \times 10^{-9}$
Diverticulum intestinal	109	220,811	27	211,125	0.26 [0.17,0.39]	$< 3.0 \times 10^{-8}$
Renal injury	556	220,364	127	211,025	0.24 [0.20,0.29]	$< 6.8 \times 10^{-57}$
Coeliac disease	143	220,777	29	211,123	0.21 [0.14,0.32]	$< 2.6 \times 10^{-14}$
Granulocytopenia	148	220,772	27	211,125	0.19 [0.13,0.29]	$< 2.4 \times 10^{-16}$
Sprue-like enteropathy	353	220,567	0	211,152	0.00 [0.00,0.00]	$< 2.4 \times 10^{-99}$

Table S8: Associations between adverse events and drugs. This table shows the number of patients who: exposed to the drug and have the adverse event (denoted by ‘A’); exposed to the drug but not have the adverse event (denoted by ‘B’); not exposed to the drug but have the adverse event (denoted by ‘C’); not exposed to the drug and not have the adverse event (denoted by ‘D’). Please note all the numbers (A, B, C, and D) are measured during the pandemic period (March 11 – September 30, 2020). We conduct patient matching and split patients into test group and control group. The size of control group is ten times of that of test group, which means that $10(A + B) = C + D$ (Methods). On the top of the statistics, we qualify the defined γ following Eq. 4 (Methods), where ‘A’, ‘B’, ‘C’, and ‘D’ denote the measurement of $f(d_j, s_h, 2020)$, $f(d_j, \neg s_h, 2020)$, $f(\neg d_j, s_h, 2020)$, and $f(\neg d_j, \neg s_h, 2020)$, respectively. The p-value is measured by Fisher’s exact test followed by Bonferroni correction. In this table, we provide the top 100 drug-adverse event pairs with the lowest p-values and sort them in descending order of γ . Higher γ and smaller p-value indicate the adverse event has stronger association with the drug. The ‘-’ denotes infinity since the denominator is zero in Eq. 4. PEx: pulmonary exacerbation; IEC: Immune effector cell.

Adverse event	Drug name	A	B	C	D	γ (95% CI) (\downarrow)	p-value
Bladder cancer	Pioglitazone	104	245	1	3,489	1,481.04 [205.79,10,659.00]	$< 5.4 \times 10^{-111}$
Vascular calcification	Warfarin	75	2,863	1	29,379	769.62 [106.97,5,537.48]	$< 1.7 \times 10^{-74}$
Delusion	Pimavanserin	269	4,212	4	44,806	715.39 [266.42,1,920.97]	$< 4.9 \times 10^{-273}$
Epstein-barr viraemia	Tacrolimus	67	2,512	1	25,789	687.84 [95.45,4,957.02]	$< 3.5 \times 10^{-66}$
Melanocytic naevus	Fingolimod	118	1,258	2	13,758	645.25 [159.30,2,613.52]	$< 5.3 \times 10^{-119}$
Hypogammaglobulinaemia	Fludarabine	148	578	3	7,257	619.40 [196.88,1,948.67]	$< 9.9 \times 10^{-153}$
Type I hypersensitivity	Famotidine	55	2,376	1	24,309	562.71 [77.83,4,068.17]	$< 1.1 \times 10^{-53}$
Haemorrhagic stroke	Rivaroxaban	99	4,546	2	46,448	505.76 [124.69,2,051.34]	$< 9.7 \times 10^{-98}$
Hypothermia	Risperidone	47	814	1	8,609	497.08 [68.49,3,607.59]	$< 1.1 \times 10^{-45}$
Diverticulum intestinal haemorrhagic	Rivaroxaban	49	4,596	1	46,449	495.21 [68.36,3,587.17]	$< 2.5 \times 10^{-47}$
Haematotoxicity	Vincristine	55	1,076	2	11,308	289.01 [70.40,1,186.47]	$< 1.5 \times 10^{-52}$
Hypogammaglobulinaemia	Cyclophosphamide	153	2,024	6	21,764	274.20 [121.13,620.69]	$< 2.8 \times 10^{-149}$
Type I hypersensitivity	Cetirizine	56	2,100	3	21,557	191.62 [59.93,612.71]	$< 4.6 \times 10^{-52}$
Hallucination	Istradefylline	78	807	7	8,843	122.10 [56.16,265.48]	$< 4.9 \times 10^{-71}$
Neurotoxicity	Tisagenlecleucel	104	391	12	4,938	109.45 [59.69,200.71]	$< 2.4 \times 10^{-95}$
Pain in jaw	Epoprostenol	378	621	142	9,848	42.21 [34.24,52.04]	$< 3.1 \times 10^{-297}$
Neoplasm progression	Axitinib	64	426	18	4,882	40.75 [23.93,69.38]	$< 4.4 \times 10^{-49}$
Neurotoxicity	Fludarabine	107	619	35	7,225	35.68 [24.15,52.72]	$< 1.9 \times 10^{-80}$
Pyrexia	Tisagenlecleucel	201	294	101	4,849	32.82 [25.15,42.85]	$< 1.7 \times 10^{-146}$
Haematuria	Rivaroxaban	181	4,464	71	46,379	26.49 [20.09,34.91]	$< 9.6 \times 10^{-127}$
Hallucination	Rasagiline	69	213	42	2,778	21.43 [14.25,32.23]	$< 8.9 \times 10^{-44}$
Hallucination	Carbidopa	404	1,569	244	19,486	20.56 [17.40,24.30]	$< 1.9 \times 10^{-259}$
Delusion	Carbidopa	102	1,871	53	19,677	20.24 [14.47,28.30]	$< 4.0 \times 10^{-65}$
Pulmonary hypertension	Macitentan	295	4,421	167	46,993	18.78 [15.49,22.76]	$< 2.1 \times 10^{-185}$
Confusional state	Pimavanserin	367	4,114	214	44,596	18.59 [15.66,22.07]	$< 1.0 \times 10^{-229}$
Rectal haemorrhage	Rivaroxaban	178	4,467	107	46,343	17.26 [13.55,21.98]	$< 3.2 \times 10^{-108}$
Internal haemorrhage	Rivaroxaban	101	4,544	60	46,390	17.19 [12.47,23.69]	$< 6.9 \times 10^{-61}$
Neurotoxicity	Cyclophosphamide	112	2,065	70	21,700	16.81 [12.43,22.74]	$< 6.4 \times 10^{-67}$
Dementia	Pimavanserin	103	4,378	65	44,745	16.20 [11.85,22.13]	$< 1.0 \times 10^{-60}$
Pyrexia	Fludarabine	207	519	175	7,085	16.15 [12.96,20.12]	$< 1.1 \times 10^{-118}$
Fluid retention	Macitentan	513	4,203	457	46,703	12.47 [10.95,14.20]	$< 8.0 \times 10^{-271}$

Hypotension	Tisagenlecleucel	87 408 87	4,863	11.92 [8.71,16.31]	< 1.8 × 10 ⁻⁴³
Bradycardia	Remdesivir	125 2,894 116	30,074	11.20 [8.67,14.46]	< 1.9 × 10 ⁻⁶²
Hallucination	Quetiapine	163 1,553 161	16,999	11.08 [8.86,13.86]	< 1.3 × 10 ⁻⁸⁰
Pain in jaw	Selexipag	261 1,617 278	18,502	10.74 [9.01,12.82]	< 1.6 × 10 ⁻¹²⁶
Pulmonary hypertension	Sildenafil	174 2,661 171	28,179	10.78 [8.69,13.36]	< 2.3 × 10 ⁻⁸⁵
Oedema peripheral	Macitentan	375 4,341 393	46,767	10.28 [8.89,11.88]	< 6.6 × 10 ⁻¹⁸⁰
Hypotension	Riociguat	252 1,273 324	14,926	9.12 [7.66,10.86]	< 2.1 × 10 ⁻¹¹⁰
Neuropathy peripheral	Bortezomib	172 1,402 215	15,525	8.86 [7.20,10.91]	< 1.0 × 10 ⁻⁷⁴
Fluid retention	Epoprostenol	150 849 199	9,791	8.69 [6.95,10.87]	< 1.3 × 10 ⁻⁶³
Dyspnoea	Oxygen	284 484 522	7,158	8.05 [6.78,9.55]	< 2.2 × 10 ⁻¹⁰⁶
Oedema peripheral	Riociguat	148 1,377 205	15,045	7.89 [6.34,9.81]	< 1.0 × 10 ⁻⁵⁹
Fluid overload	Sildenafil	132 2,703 176	28,174	7.82 [6.22,9.83]	< 1.8 × 10 ⁻⁵³
Confusional state	Carbidopa	144 1,829 202	19,528	7.61 [6.11,9.48]	< 5.2 × 10 ⁻⁵⁷
Fluid overload	Macitentan	191 4,525 263	46,897	7.53 [6.23,9.09]	< 5.6 × 10 ⁻⁷⁶
Dyspnoea	Epoprostenol	405 594 846	9,144	7.37 [6.38,8.52]	< 1.3 × 10 ⁻¹³⁹
Hypotension	Sacubitril	148 1,396 226	15,214	7.14 [5.76,8.84]	< 1.0 × 10 ⁻⁵⁵
Pain in jaw	Tadalafil	218 1,784 340	19,680	7.07 [5.93,8.44]	< 1.0 × 10 ⁻⁸¹
Fluid retention	Riociguat	152 1,373 236	15,014	7.04 [5.70,8.70]	< 1.2 × 10 ⁻⁵⁶
Respiratory failure	Remdesivir	119 2,900 176	30,014	7.00 [5.53,8.86]	< 1.3 × 10 ⁻⁴⁴
Pain in jaw	Sildenafil	255 2,580 396	27,954	6.98 [5.93,8.21]	< 2.7 × 10 ⁻⁹⁵
Chest pain	Epoprostenol	171 828 287	9,703	6.98 [5.70,8.55]	< 4.7 × 10 ⁻⁶²
Cardiac arrest	Remdesivir	128 2,891 191	29,999	6.95 [5.54,8.73]	< 8.4 × 10 ⁻⁴⁸
Pyrexia	Cyclophosphamide	258 1,919 421	21,349	6.82 [5.80,8.02]	< 5.0 × 10 ⁻⁹⁴
Dyspnoea	Treprostinil	789 2,041 1,520	26,780	6.81 [6.18,7.51]	< 5.8 × 10 ⁻²⁷³
Fluid retention	Sildenafil	236 2,599 380	27,970	6.68 [5.65,7.90]	< 1.5 × 10 ⁻⁸⁵
Pain in jaw	Macitentan	379 4,337 622	46,538	6.54 [5.73,7.46]	< 9.4 × 10 ⁻¹³⁶
Hypotension	Macitentan	450 4,266 755	46,405	6.48 [5.75,7.32]	< 1.2 × 10 ⁻¹⁵⁹
Dyspnoea	Selexipag	576 1,302 1,212	17,568	6.41 [5.72,7.19]	< 3.7 × 10 ⁻¹⁸⁷
Pain in jaw	Riociguat	152 1,373 263	14,987	6.31 [5.13,7.76]	< 4.5 × 10 ⁻⁵²
Gait disturbance	Pimavanserin	168 4,313 290	44,520	5.98 [4.93,7.25]	< 2.8 × 10 ⁻⁵⁶
Fluid retention	Tadalafil	196 1,806 360	19,660	5.93 [4.95,7.10]	< 3.7 × 10 ⁻⁶⁴
Chest pain	Macitentan	375 4,341 678	46,482	5.92 [5.20,6.74]	< 2.9 × 10 ⁻¹²⁴
Fluid retention	Selexipag	165 1,713 302	18,478	5.89 [4.84,7.17]	< 9.1 × 10 ⁻⁵⁴
Dyspnoea	Sildenafil	753 2,082 1,639	26,711	5.89 [5.35,6.50]	< 2.2 × 10 ⁻²³²
Dyspnoea	Tadalafil	569 1,433 1,293	18,727	5.75 [5.14,6.43]	< 4.4 × 10 ⁻¹⁷⁰
Neuropathy peripheral	Acyclovir	247 4,094 458	42,952	5.66 [4.83,6.63]	< 4.9 × 10 ⁻⁷⁹
Pain in extremity	Epoprostenol	187 812 391	9,599	5.65 [4.68,6.83]	< 7.4 × 10 ⁻⁵⁷
Hypotension	Selexipag	209 1,669 412	18,368	5.58 [4.69,6.64]	< 8.7 × 10 ⁻⁶⁵
Pain in jaw	Treprostinil	216 2,614 415	27,885	5.55 [4.69,6.58]	< 1.8 × 10 ⁻⁶⁷
Cough	Treprostinil	314 2,516 633	27,667	5.45 [4.74,6.28]	< 7.4 × 10 ⁻⁹⁶
Oedema peripheral	Sildenafil	166 2,669 321	28,029	5.43 [4.48,6.58]	< 6.5 × 10 ⁻⁵¹
Cough	Macitentan	524 4,192 1,103	46,057	5.22 [4.68,5.82]	< 2.6 × 10 ⁻¹⁵⁴
Chest discomfort	Macitentan	200 4,516 402	46,758	5.15 [4.34,6.12]	< 5.2 × 10 ⁻⁵⁹
Dyspnoea	Riociguat	419 1,106 1,045	14,205	5.15 [4.53,5.86]	< 2.9 × 10 ⁻¹¹³
Neuropathy peripheral	Dexamethasone	358 6,844 746	71,274	5.00 [4.40,5.68]	< 3.3 × 10 ⁻¹⁰³
Pain in extremity	Selexipag	245 1,633 557	18,223	4.91 [4.19,5.75]	< 4.1 × 10 ⁻⁶⁷

Chest pain	Sildenafil	210	2,625	473	27,877	4.71	[3.99,5.57]	$< 2.3 \times 10^{-56}$
Arthralgia	Selexipag	230	1,648	556	18,224	4.57	[3.89,5.38]	$< 7.9 \times 10^{-59}$
Neuropathy peripheral	Pomalidomide	195	4,150	462	42,988	4.37	[3.69,5.18]	$< 6.6 \times 10^{-49}$
Cough	Tadalafil	213	1,789	557	19,463	4.16	[3.53,4.91]	$< 1.9 \times 10^{-49}$
Pneumonia	Macitentan	541	4,175	1,614	45,546	3.66	[3.30,4.05]	$< 1.1 \times 10^{-108}$
Cough	Sildenafil	242	2,593	747	27,603	3.45	[2.97,4.01]	$< 3.3 \times 10^{-45}$
Pain in extremity	Macitentan	424	4,292	1,378	45,782	3.28	[2.93,3.68]	$< 1.5 \times 10^{-74}$
Type I hypersensitivity	Oxaliplatin	70	456	0	5,260	--		$< 1.1 \times 10^{-72}$
Haematotoxicity	Methotrexate	44	4,682	0	47,260	--		$< 9.4 \times 10^{-44}$
Diffuse large b-cell lymphoma recurrent	Tisagenlecleucel	44	451	0	4,950	--		$< 1.8 \times 10^{-44}$
Haematotoxicity	Carboplatin	46	862	0	9,080	--		$< 3.2 \times 10^{-46}$
Haematotoxicity	Thiotepa	46	113	0	1,590	--		$< 1.2 \times 10^{-48}$
Hypogammaglobulinaemia	Tisagenlecleucel	151	344	0	4,950	--		$< 2.5 \times 10^{-165}$
Neutrophilia	Clozapine	238	1,756	0	19,940	--		$< 1.5 \times 10^{-251}$
Haematotoxicity	Cisplatin	53	531	0	5,840	--		$< 5.2 \times 10^{-54}$
Haematotoxicity	Cyclophosphamide	55	2,122	0	21,770	--		$< 2.1 \times 10^{-55}$
Haematotoxicity	Etoposide	55	705	0	7,600	--		$< 6.4 \times 10^{-56}$

Table S9: Associations between drug-adverse event pairs and the pandemic. The ‘Occur 2019’ and ‘Nonoccur 2019’ denote the number of submitted reports that contain and not contain the specific drug-adverse event pair in 2019 (March 11 – September 30), respectively. Similarly, ‘Occur 2020’ and ‘Nonoccur 2020’ denote the statistics in the same period of 2020. On the basis of these numbers, we calculate the defined δ following Eq. 5 (Methods). The p-value is measured by Fisher’s exact test followed by Bonferroni correction. We provide the top 100 drug-adverse event pairs with the lowest p-values. Then, the pairs are sorted in descending order of δ . Higher δ and smaller p-value indicate the pair has stronger connection with the pandemic. The ‘- -’ denotes infinity since the denominator is zero in Eq. 5. PEx: pulmonary exacerbation; IEC: Immune effector cell.

Adverse event	Drug name	Occur 2019	Nonoccur 2019	Occur 2020	Nonoccur 2020	δ (95% CI) (\downarrow)	p-value
Hypogammaglobulinaemia	Tisagenlecleucel	1	220,919	151	211,001	158.10 [22.13,1,129.69]	$< 5.2 \times 10^{-41}$
Cough	Elexacaftor	1	220,919	120	211,032	125.62 [17.55,899.14]	$< 1.8 \times 10^{-31}$
Respiratory arrest	Alprazolam	1	220,919	98	211,054	102.58 [14.31,735.56]	$< 1.9 \times 10^{-24}$
Vascular calcification	Warfarin	1	220,919	75	211,077	78.50 [10.91,564.59]	$< 1.5 \times 10^{-17}$
Hypogammaglobulinaemia	Fludarabine	2	220,918	149	211,003	78.00 [19.33,314.80]	$< 9.0 \times 10^{-39}$
Hypoxia	Fludarabine	1	220,919	60	211,092	62.79 [8.70,453.10]	$< 5.3 \times 10^{-13}$
Haematotoxicity	Etoposide	1	220,919	55	211,097	57.56 [7.97,415.95]	$< 1.7 \times 10^{-11}$
Bladder cancer	Pioglitazone	2	220,918	104	211,048	54.43 [13.43,220.56]	$< 4.2 \times 10^{-25}$
Hypogammaglobulinaemia	Cyclophosphamide	4	220,916	154	210,998	40.31 [14.94,108.77]	$< 2.0 \times 10^{-37}$
Haematotoxicity	Vincristine	2	220,918	55	211,097	28.78 [7.02,117.99]	$< 2.9 \times 10^{-10}$
Respiratory arrest	Fentanyl	3	220,917	73	211,079	25.47 [8.03,80.81]	$< 1.2 \times 10^{-14}$
Respiratory arrest	Oxycodone	3	220,917	62	211,090	21.63 [6.79,68.90]	$< 3.3 \times 10^{-11}$
Pain in extremity	Certolizumab pegol	4	220,916	77	211,075	20.15 [7.37,55.05]	$< 8.8 \times 10^{-15}$
Dyspnoea	Certolizumab pegol	4	220,916	63	211,089	16.48 [6.00,45.29]	$< 1.7 \times 10^{-10}$
Respiratory arrest	Acetaminophen	8	220,912	114	211,038	14.92 [7.28,30.55]	$< 1.6 \times 10^{-21}$
Psoriatic arthropathy	Certolizumab pegol	8	220,912	95	211,057	12.43 [6.04,25.58]	$< 2.8 \times 10^{-16}$
Internal haemorrhage	Rivaroxaban	9	220,911	101	211,051	11.75 [5.94,23.23]	$< 4.2 \times 10^{-17}$
Arthralgia	Certolizumab pegol	16	220,904	175	210,977	11.45 [6.86,19.11]	$< 8.2 \times 10^{-32}$
Hypoxia	Cyclophosphamide	8	220,912	76	211,076	9.94 [4.80,20.60]	$< 3.9 \times 10^{-11}$
Haemorrhagic stroke	Rivaroxaban	11	220,909	99	211,053	9.42 [5.05,17.56]	$< 4.8 \times 10^{-15}$
Rectal haemorrhage	Rivaroxaban	22	220,898	179	210,973	8.52 [5.47,13.27]	$< 8.9 \times 10^{-29}$
Cardiac arrest	Alprazolam	15	220,905	117	211,035	8.16 [4.77,13.98]	$< 3.1 \times 10^{-17}$
Neurotoxicity	Tisagenlecleucel	14	220,906	104	211,048	7.78 [4.45,13.59]	$< 1.5 \times 10^{-14}$
Hypotension	Fludarabine	12	220,908	88	211,064	7.68 [4.20,14.03]	$< 1.5 \times 10^{-11}$
Hypotension	Tisagenlecleucel	12	220,908	87	211,065	7.59 [4.15,13.88]	$< 2.8 \times 10^{-11}$
Pyrexia	Fludarabine	30	220,890	208	210,944	7.26 [4.95,10.65]	$< 3.3 \times 10^{-31}$
Neurotoxicity	Fludarabine	16	220,904	107	211,045	7.00 [4.14,11.84]	$< 4.6 \times 10^{-14}$
Tremor	Pimavanserin	14	220,906	93	211,059	6.95 [3.96,12.20]	$< 1.5 \times 10^{-11}$
Dementia	Pimavanserin	17	220,903	103	211,049	6.34 [3.80,10.59]	$< 1.7 \times 10^{-12}$
Gastrointestinal haemorrhage	Rivaroxaban	143	220,777	855	210,297	6.28 [5.26,7.49]	$< 8.2 \times 10^{-127}$
Pyrexia	Tisagenlecleucel	34	220,886	201	210,951	6.19 [4.30,8.90]	$< 3.8 \times 10^{-27}$
Confusional state	Pimavanserin	66	220,854	367	210,785	5.83 [4.48,7.57]	$< 5.2 \times 10^{-50}$
Hallucination	Pimavanserin	210	220,710	1,145	210,007	5.73 [4.95,6.64]	$< 4.0 \times 10^{-161}$
Haematuria	Rivaroxaban	36	220,884	183	210,969	5.32 [3.72,7.61]	$< 8.2 \times 10^{-22}$
Gait disturbance	Pimavanserin	35	220,885	168	210,984	5.03 [3.49,7.23]	$< 1.1 \times 10^{-18}$
Delusion	Pimavanserin	57	220,863	269	210,883	4.94 [3.71,6.58]	$< 1.2 \times 10^{-31}$
Hypotension	Cyclophosphamide	24	220,896	113	211,039	4.93 [3.17,7.66]	$< 3.0 \times 10^{-11}$
Neurotoxicity	Cyclophosphamide	24	220,896	112	211,040	4.88 [3.14,7.59]	$< 5.1 \times 10^{-11}$
Melanocytic naevus	Fingolimod	27	220,893	118	211,034	4.57 [3.01,6.95]	$< 5.7 \times 10^{-11}$
Cough	Epoprostenol	31	220,889	134	211,018	4.52 [3.06,6.69]	$< 6.5 \times 10^{-13}$
Chest pain	Epoprostenol	41	220,879	171	210,981	4.37 [3.11,6.14]	$< 8.4 \times 10^{-17}$
Arthralgia	Riociguat	30	220,890	125	211,027	4.36 [2.93,6.50]	$< 2.2 \times 10^{-11}$
Hypoaacusis	Pregabalin	33	220,887	129	211,023	4.09 [2.79,6.00]	$< 5.5 \times 10^{-11}$
Cardiac arrest	Acetaminophen	46	220,874	177	210,975	4.03 [2.91,5.57]	$< 5.2 \times 10^{-16}$
Hallucination	Carbidopa	106	220,814	404	210,748	3.99 [3.22,4.95]	$< 3.1 \times 10^{-40}$

Neuropathy peripheral	Lenalidomide	236	220,684	844	210,308	3.75 [3.25,4.34]	$< 2.5 \times 10^{-82}$
Pain in jaw	Macitentan	109	220,811	379	210,773	3.64 [2.94,4.51]	$< 5.1 \times 10^{-34}$
Hallucination	Quetiapine	47	220,873	163	210,989	3.63 [2.62,5.02]	$< 9.5 \times 10^{-13}$
Pain in extremity	Epoprostenol	55	220,865	187	210,965	3.56 [2.64,4.81]	$< 1.3 \times 10^{-14}$
Chest discomfort	Macitentan	60	220,860	201	210,951	3.51 [2.63,4.68]	$< 9.1 \times 10^{-16}$
Fluid retention	Epoprostenol	45	220,875	150	211,002	3.49 [2.50,4.87]	$< 1.0 \times 10^{-10}$
Cough	Riociguat	46	220,874	152	211,000	3.46 [2.49,4.81]	$< 1.0 \times 10^{-10}$
Pyrexia	Cyclophosphamide	79	220,841	259	210,893	3.43 [2.67,4.42]	$< 1.3 \times 10^{-20}$
Urinary tract infection	Macitentan	59	220,861	193	210,959	3.42 [2.56,4.58]	$< 1.5 \times 10^{-14}$
Pain in jaw	Sildenafil	78	220,842	255	210,897	3.42 [2.66,4.41]	$< 3.7 \times 10^{-20}$
Arthralgia	Macitentan	97	220,823	313	210,839	3.38 [2.69,4.24]	$< 3.6 \times 10^{-25}$
Insomnia	Macitentan	52	220,868	168	210,984	3.38 [2.48,4.62]	$< 5.8 \times 10^{-12}$
Pain in extremity	Macitentan	133	220,787	425	210,727	3.35 [2.76,4.07]	$< 6.6 \times 10^{-35}$
Pyrexia	Macitentan	84	220,836	257	210,895	3.20 [2.50,4.10]	$< 1.6 \times 10^{-18}$
Cough	Macitentan	176	220,744	526	210,626	3.13 [2.64,3.72]	$< 2.7 \times 10^{-40}$
Chest pain	Macitentan	126	220,794	376	210,776	3.13 [2.55,3.83]	$< 7.9 \times 10^{-28}$
Neuropathy peripheral	Acyclovir	86	220,834	251	210,901	3.06 [2.39,3.90]	$< 8.8 \times 10^{-17}$
Pain in jaw	Epoprostenol	134	220,786	378	210,774	2.95 [2.43,3.60]	$< 9.7 \times 10^{-26}$
Oedema peripheral	Macitentan	135	220,785	376	210,776	2.92 [2.40,3.55]	$< 4.3 \times 10^{-25}$
Neuropathy peripheral	Dexamethasone	134	220,786	362	210,790	2.83 [2.32,3.45]	$< 6.2 \times 10^{-23}$
Dyspnoea	Epoprostenol	152	220,768	405	210,747	2.79 [2.32,3.36]	$< 2.0 \times 10^{-25}$
Neuropathy peripheral	Acetaminophen	76	220,844	199	210,953	2.74 [2.10,3.57]	$< 2.1 \times 10^{-10}$
Arthralgia	Selexipag	93	220,827	231	210,921	2.60 [2.04,3.31]	$< 2.3 \times 10^{-11}$
Hypotension	Riociguat	103	220,817	253	210,899	2.57 [2.05,3.23]	$< 1.5 \times 10^{-12}$
Neutrophilia	Clozapine	98	220,822	239	210,913	2.55 [2.02,3.23]	$< 1.5 \times 10^{-11}$
Pain in extremity	Sildenafil	102	220,818	239	210,913	2.45 [1.95,3.09]	$< 1.4 \times 10^{-10}$
Hypotension	Macitentan	194	220,726	451	210,701	2.44 [2.06,2.88]	$< 2.0 \times 10^{-22}$
Fluid retention	Macitentan	224	220,696	515	210,637	2.41 [2.06,2.82]	$< 1.6 \times 10^{-25}$
Dyspnoea	Macitentan	672	220,248	1,518	209,634	2.37 [2.17,2.60]	$< 5.4 \times 10^{-79}$
Pulmonary hypertension	Macitentan	132	220,788	295	210,857	2.34 [1.91,2.87]	$< 1.9 \times 10^{-12}$
Dyspnoea	Riociguat	202	220,718	421	210,731	2.18 [1.85,2.58]	$< 2.9 \times 10^{-16}$
Dyspnoea	Sildenafil	375	220,545	753	210,399	2.10 [1.86,2.38]	$< 5.2 \times 10^{-29}$
Dyspnoea	Selexipag	300	220,620	577	210,575	2.02 [1.75,2.32]	$< 3.3 \times 10^{-19}$
Pneumonia	Macitentan	286	220,634	541	210,611	1.98 [1.72,2.29]	$< 5.5 \times 10^{-17}$
Dyspnoea	Apixaban	212	220,708	396	210,756	1.96 [1.66,2.31]	$< 4.5 \times 10^{-11}$
Neoplasm progression	Palbociclib	248	220,672	443	210,709	1.87 [1.60,2.19]	$< 4.9 \times 10^{-11}$
Dyspnoea	MP glycol-epoetin beta	138	220,782	32	211,120	0.24 [0.17,0.36]	$< 3.6 \times 10^{-11}$
Pyrexia	Deflazacort	50	220,870	0	211,152	0.00 [0.00,0.00]	$< 1.8 \times 10^{-10}$
Haematotoxicity	Carboplatin	0	220,920	46	211,106	--	$< 3.0 \times 10^{-10}$
Cardiac arrest	Remdesivir	0	220,920	128	211,024	--	$< 9.5 \times 10^{-36}$
Haematotoxicity	Cisplatin	0	220,920	53	211,099	--	$< 2.0 \times 10^{-12}$
Insomnia	Elexacaftor	0	220,920	55	211,097	--	$< 4.8 \times 10^{-13}$
Hypotension	Remdesivir	0	220,920	117	211,035	--	$< 2.5 \times 10^{-32}$
Respiratory failure	Remdesivir	0	220,920	119	211,033	--	$< 6.0 \times 10^{-33}$
Type I hypersensitivity	Cetirizine	0	220,920	56	211,096	--	$< 2.3 \times 10^{-13}$
Bradycardia	Remdesivir	0	220,920	125	211,027	--	$< 8.1 \times 10^{-35}$
Insomnia	Istradefylline	0	220,920	49	211,103	--	$< 3.5 \times 10^{-11}$
Hypoxia	Remdesivir	0	220,920	100	211,052	--	$< 4.9 \times 10^{-27}$
Type I hypersensitivity	Famotidine	0	220,920	55	211,097	--	$< 4.8 \times 10^{-13}$
Dyspnoea	Remdesivir	0	220,920	67	211,085	--	$< 9.0 \times 10^{-17}$
Shock haemorrhagic	Rivaroxaban	0	220,920	49	211,103	--	$< 3.5 \times 10^{-11}$
Tremor	Istradefylline	0	220,920	47	211,105	--	$< 1.4 \times 10^{-10}$
Type I hypersensitivity	Oxaliplatin	0	220,920	70	211,082	--	$< 1.0 \times 10^{-17}$
Hallucination	Istradefylline	0	220,920	78	211,074	--	$< 3.4 \times 10^{-20}$
Haematotoxicity	Thiotepa	0	220,920	46	211,106	--	$< 3.0 \times 10^{-10}$